Cosmos Holdings Inc. (COSM): History, Ownership, Mission, How It Works & Makes Money

Cosmos Holdings Inc. (COSM) just reported a Q3 2025 revenue increase of 38% to $17.11 million and a record gross margin of 15.21%, but does that stellar growth truly reflect a stable, long-term business model?

The company is a diversified healthcare group that's not only expanding its high-margin proprietary nutraceutical brand, Sky Premium Life, globally but is also aggressively building a digital asset treasury with a $300 million financing facility, a strategic move that defintely raises eyebrows in the traditional pharmaceutical space.

You're looking for a clear map of how a vertically integrated distributor, backed by significant insider ownership at 23.27%, balances core healthcare logistics with a bold crypto strategy, so let's unpack the history, ownership, and precise mechanics of how Cosmos Holdings Inc. works and makes its money.

Cosmos Holdings Inc. (COSM) History

Cosmos Holdings Inc. (COSM), now officially Cosmos Health Inc., began its journey as a regional pharmaceutical distributor in Greece before transforming into a diversified, vertically integrated global healthcare group. The company's evolution is marked by a clear shift from wholesale distribution to developing and marketing its own high-margin proprietary nutraceuticals (dietary supplements), a strategy that is paying off with record financial results in 2025.

Given Company's Founding Timeline

Year established

The company was initially established in 2009.

Original location

The founding and initial operations were centered in Thessaloniki, Greece, which remains a key operational hub. Today, the corporate headquarters is in Chicago, Illinois, USA.

Founding team members

The key figure associated with the company's founding and continued leadership is Grigorios Siokas, who serves as the Chief Executive Officer and Chairman of the Board.

Initial capital/funding

Specific details on the initial seed capital or funding are not publicly disclosed. The company later gained access to capital markets through its Initial Public Offering (IPO) in 2017.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The most significant transformations have centered on vertical integration, a drive for higher-margin products, and a bold move into digital asset management to diversify the balance sheet.

The recent strategic focus on proprietary brands like Sky Premium Life is a game-changer. For example, the U.S. launch of the Sky Premium Life brand is expected to yield strong gross margins of approximately 75%, with the NOOR Collagen product alone projected to generate over $12 million in annualized revenue.

The third quarter of the 2025 fiscal year marked a major financial turning point, showing the strategy is working. The company reported record Q3 2025 revenue of $17.11 million, a 38% increase from Q3 2024, and a record gross profit of $2.60 million, up 116% year-over-year. That's a huge jump in profitability.

The company has also made an unconventional move for a healthcare group, committing to a digital asset strategy:

• Secured a $300 million digital financing facility to strengthen long-term diversification and balance sheet resilience.
• Commenced purchases of Ethereum, with total holdings reaching $2 million by October 2025.
• Launched a new nanotechnology R&D program in October 2025 to develop next-generation nutraceutical formulas with enhanced phytochemical efficacy.

This mix of high-margin product expansion, record financial performance, and a defintely unique digital asset strategy shows a company aggressively pursuing a global healthcare powerhouse vision. You can dive deeper into who is funding this evolution here: Exploring Cosmos Holdings Inc. (COSM) Investor Profile: Who's Buying and Why?

Cosmos Holdings Inc. (COSM) Ownership Structure

Cosmos Holdings Inc. (which now operates as Cosmos Health Inc.) is a publicly traded entity with a highly concentrated insider stake, meaning a small group of executives holds significant control over the company's direction. This structure, where the CEO's ownership is nearly 20%, gives the management team a strong voice in strategic decisions, but it also leaves the stock with a large retail float, which can lead to higher volatility.

Cosmos Health Inc.'s Current Status

The company, trading on the Nasdaq Capital Market under the ticker COSM, remains a publicly listed global healthcare group as of November 2025. Its market capitalization was approximately $22.4 million as of November 14, 2025, reflecting its small-cap status and the inherent risks that come with it. The stock is considered thinly traded, with an average daily volume around 740,330 shares, which can amplify price swings.

For the nine months ended September 30, 2025, Cosmos Health Inc. reported revenue of $45.57 million, an increase of 13% from the prior year, showing clear top-line growth. Still, the company reported a net loss of $5.35 million in Q3 2025, so while they are growing, profitability is defintely a work in progress. You need to watch that debt-to-equity ratio, which stood at 0.91 as of the end of Q3 2025, indicating a balanced but tight liquidity position with a current ratio of 0.99.

Cosmos Health Inc.'s Ownership Breakdown

The ownership structure is unusual for a Nasdaq-listed company, characterized by a dominant insider position and a very high percentage of shares held by retail investors. This means the CEO's interests are very closely aligned with shareholder value, but institutional oversight is relatively low.

Cosmos Health Inc.'s Leadership

The leadership team is seasoned, with an average tenure of about five years, providing stability in a high-growth sector. The strategic direction is heavily influenced by the Chairman and CEO, who is also the largest individual shareholder, which is a key factor in understanding the firm's long-term commitment to its Mission Statement, Vision, & Core Values of Cosmos Holdings Inc. (COSM).

The core management and board, as of November 2025, includes:

• Grigorios Siokas: Chairman and Chief Executive Officer (CEO). He has served in this role since February 2016 and is the primary driver of the company's strategy. His total compensation for 2024 was $2.72 million.
• Georgios Terzis: Chief Financial Officer (CFO). He manages the financial operations and capital structure, a critical role given the recent digital asset investments.
• Nikolaos Bardakis: Chief Operating Officer (COO). He oversees the day-to-day business and operational efficiency.
• Dimitris Moraitis: Vice President of Strategy & Operations. Appointed in February 2025, he is tasked with optimizing operational processes and driving strategic initiatives.

The Board of Directors, which was recently elected in September 2025, includes Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos, ensuring governance oversight for the company's diversified healthcare and nutraceutical business.

Cosmos Holdings Inc. (COSM) Mission and Values

Cosmos Health Inc.'s core purpose transcends simple pharmaceutical distribution; it's about closing the gap in healthcare access and driving innovation, which is why the company rebranded to reflect its broader health and wellness focus.

This commitment to quality and expansion isn't just rhetoric; it's a strategy that has propelled their nine-month 2025 revenue to $45.57 million and pushed their gross profit to $5.82 million, a 76% increase from the prior-year period. You can defintely see the mission in the numbers.

Cosmos Health Inc.'s Core Purpose

The company's foundational purpose is to act as a vertically integrated global healthcare group, ensuring essential, high-quality products-from branded generics to proprietary nutraceuticals-reach consumers efficiently across Europe and, increasingly, the US market.

Here's the quick math: expanding high-margin segments, like their proprietary Sky Premium Life brand, directly translates their mission into superior financial performance, driving the Q3 2025 gross margin to a record 15.21%. Breaking Down Cosmos Holdings Inc. (COSM) Financial Health: Key Insights for Investors

Official Mission Statement

While a single, static mission statement can be corporate filler, Cosmos Health Inc.'s operations point to a clear, multi-faceted mandate:

• Improve Healthcare Access: Ensure essential pharmaceutical and nutraceutical products are available where needed.
• Provide Quality Products: Distribute high-quality, safe, and effective healthcare products and medical devices.
• Expand Market Reach: Strategically grow presence in key global markets to serve a broader customer base.

Honestly, the mission is simply to be a reliable, quality-focused conduit for global health and wellness products.

Vision Statement

The company's vision is focused on transformation and long-term value creation for all stakeholders, moving beyond just distribution to encompass R&D and manufacturing.

• Become a Leading International Healthcare Company: Be recognized for quality, innovation, and customer satisfaction.
• Drive Innovation: Embrace new technologies, like their Cloudscreen AI platform for drug repurposing, and specialized R&D in nutraceuticals.
• Achieve Sustainable Growth: Create long-term value, as reflected by the strengthening of their balance sheet, which showed Total Assets of $61.84 million as of June 30, 2025.

The vision is to be a global powerhouse, not just a distributor.

Cosmos Health Inc. Slogan/Tagline

Cosmos Health Inc. does not heavily promote a single, catchy tagline, preferring to let their core values and actions speak for themselves. Their focus is on the operational principles that guide their daily work, which are more valuable to an investor than a marketing slogan.

Their core values, which form the cultural DNA, are the real message:

• Quality: Adherence to the strictest standards, including rigorous Good Manufacturing Practices (GMP).
• Innovation: Continually pushing limits to advance the health and wellness sector, including new R&D programs in nanotechnology.
• Transparency: Being open, accountable, and reliable across all operations.
• Partnership: Collaborating with purpose to maximize impact.

What this estimate hides is that the consistent application of these values is what drives the 116% year-over-year increase in Q3 2025 Gross Profit.

Cosmos Health Inc. (COSM) How It Works

Cosmos Health Inc. operates as a diversified, vertically integrated global healthcare group, driving value by manufacturing and distributing both proprietary, high-margin nutraceutical brands and a broad portfolio of essential pharmaceutical products across Europe and the US. The company makes money by leveraging its owned manufacturing facilities and extensive distribution network to capture margin across the entire supply chain, shifting its focus toward higher-profit segments like contract manufacturing and its own branded products.

Cosmos Health Inc.'s Product/Service Portfolio

Cosmos Health Inc.'s Operational Framework

The company's operational framework is built on a vertical integration model that controls the entire value chain, from R&D to final delivery, which is how they manage to expand their gross margin. For the nine months ended September 30, 2025, this focus helped push gross profit up 76% to $5.82 million compared to the prior-year period.

Here's the quick math: the shift to higher-margin products like nutraceuticals and contract manufacturing drove the gross margin to a record 15.21% in Q3 2025, a significant jump from 9.72% a year earlier. This is a clear indicator that the strategy is working. The core process is simple: acquire, manufacture, and distribute.

• Manufacturing & Quality: Owns Cana Laboratories, which is European Medicines Agency (EMA) certified, ensuring compliance and quality control for its products, plus US-based, FDA-registered facilities for its American-market nutraceuticals.
• Logistics & Distribution: Utilizes an extensive global network, including 12 distribution centers and 85,000 square meters of warehousing space, ensuring broad market access across Europe and beyond.
• Financial Innovation: Secured a $300 million digital financing facility in Q3 2025, which they are using to enhance their balance sheet and invest in digital assets like Ethereum (ETH), a non-traditional move for a healthcare group.

To be fair, managing a diversified portfolio across multiple continents is complex, but the vertical setup helps them mitigate cross-border logistical and tariff risks, especially with the new US local manufacturing. You can find more on their guiding principles in their Mission Statement, Vision, & Core Values of Cosmos Holdings Inc. (COSM).

Cosmos Health Inc.'s Strategic Advantages

The real edge for Cosmos Health Inc. lies in three reinforcing pillars: their structure, product mix, and commitment to innovation. This combination is what allowed them to report a record Q3 2025 revenue of $17.11 million.

• Vertical Integration: Full control over manufacturing and distribution, which guarantees quality, reduces costs, and allows for faster scalability of proprietary brands.
• High-Margin Focus: Strategic pivot toward nutraceuticals and Contract Manufacturing, which carry gross margins as high as 75% for the US-based Sky Premium Life operations, significantly improving overall profitability.
• Global Diversification: Operating across multiple segments-from R&D and pharmaceuticals to consumer brands and logistics-reduces reliance on any single revenue stream or geographic market.
• Innovation and Digital Assets: Embedding innovation through AI-enabled platforms like Cloudscreen and utilizing blockchain-enhanced treasury and supply chain systems for efficiency and financial flexibility.

They are defintely moving away from being just a low-margin distributor, which is a smart, actionable shift for long-term value creation. The goal is to build a scalable platform, and the Q3 2025 results show that momentum is accelerating.

Cosmos Holdings Inc. (COSM) How It Makes Money

Cosmos Holdings Inc. primarily generates revenue as a diversified, vertically integrated global healthcare group, making money through two core channels: the high-volume wholesale distribution of pharmaceuticals and the higher-margin sales of its proprietary nutraceutical and pharmaceutical brands and contract manufacturing services.

You need to see this as a two-engine model: the large, low-margin distribution engine provides the bulk of the sales volume, while the smaller, high-margin proprietary engine drives the critical gross profit expansion. The company's recent strategic pivot is all about fueling that second, more profitable engine.

Cosmos Holdings Inc.'s Revenue Breakdown

Based on the latest available nine-month financial data for 2025, and aligning with the company's stated strategic shift toward higher-margin products, the revenue splits show where the sales volume sits versus where the profit leverage is being built. Total revenue for the nine months ended September 30, 2025, was $45.57 million.

Business Economics

The core economic reality for Cosmos Holdings Inc. is a low-margin distribution business subsidizing the growth of a high-margin proprietary business. The wholesale logistics distribution segment, which includes operations like CosmoFarm, still accounts for the majority of revenue, but it operates on thin margins, historically around 8.0%.

The real opportunity lies in the Proprietary Brands and Contract Manufacturing segment. Honestly, this is the part that changes the investment thesis.

• Pricing Power: Proprietary brands like Sky Premium Life and Mediterranation command premium pricing and significantly higher gross margins. The U.S. launch of Sky Premium Life, for example, is targeting gross margins of approximately 75%.
• Contract Manufacturing: The Cana Laboratories subsidiary manufactures pharmaceuticals and nutraceuticals for third parties, providing a steady, high-margin revenue stream (Contract Manufacturing Organization or CMO). This division is seeing a 'continued ramp-up.'
• Geographic Concentration: A significant portion of the revenue is still concentrated in Greece, though the global expansion of proprietary brands into the U.K. (through Decahedron) and the U.S. is the key growth driver.
• Strategic De-risking: The company is strategically reducing lower-margin, promotional-dependent wholesale activities, even if it means a temporary dip in total revenue for that segment, to improve the overall product mix and profitability.

Cosmos Holdings Inc.'s Financial Performance

The Q3 2025 results, released in November 2025, show a clear inflection point driven by the strategic shift, even as the company continues to report a net loss due to non-cash charges.

• Revenue Growth: Q3 2025 revenue hit a record $17.11 million, an increase of 38% compared to Q3 2024. Trailing twelve-month revenue stands at $59.79 million.
• Gross Profit Surge: Gross profit for Q3 2025 soared 116% to $2.60 million, the highest quarterly gross profit in company history.
• Margin Expansion: Gross margin expanded to a record 15.21% in Q3 2025, a significant improvement from 9.72% a year earlier. This margin expansion is the defintely most important indicator of the strategy working.
• Profitability Trend: While the reported net loss for Q3 2025 was $5.35 million (due primarily to non-cash charges like derivatives and convertible notes), the Adjusted Earnings Per Share (Adjusted EPS) for the nine-month period turned positive at $0.02.
• Balance Sheet: The company ended Q3 2025 with $4.63 million in cash and cash equivalents, a sharp increase from $0.66 million at the end of Q2 2025, partially supported by a new $300 million digital financing facility.

The narrowing operating loss, which improved to a loss of $1.82 million in Q3 2025 from a loss of $2.24 million in Q3 2024, shows that the revenue growth is finally outpacing the increase in operating expenses. You can dive deeper into the sustainability of these numbers by Breaking Down Cosmos Holdings Inc. (COSM) Financial Health: Key Insights for Investors.

Cosmos Holdings Inc. (COSM) Market Position & Future Outlook

Cosmos Holdings Inc. is at a critical inflection point in 2025, strategically pivoting away from low-margin wholesale distribution toward high-margin proprietary brands and contract manufacturing, a move designed to drive the company toward its goal of achieving profitability and positive operating cash flow this year. This shift, however, positions the company as a niche, high-growth-potential player in a massive, consolidated global healthcare market.

Competitive Landscape

When you look at Cosmos Holdings Inc. (COSM), you have to understand that its competitive landscape is defined by a deep chasm between its niche, vertically integrated model and the sheer scale of the industry giants. Cosmos is a small-cap player, focused on proprietary nutraceuticals and specialized distribution, competing against massive, global distributors.

Here's the quick math: Cosmos Holdings Inc.'s trailing twelve-month revenue is around $59.79 million, while the global pharmaceutical wholesale market is projected to be about $1.57 trillion in 2025. That puts Cosmos's market share at a tiny fraction, but its advantage isn't volume-it's the higher 75% gross margins it expects from its proprietary products, which the giants can't easily replicate.

Opportunities & Challenges

The company's future trajectory hinges on a few key, high-stakes initiatives. For every opportunity to capture high-margin revenue, there's an equal and opposite risk tied to execution and liquidity. You need to watch both sides defintely.

Industry Position

Cosmos Holdings Inc. is a diversified, vertically integrated global healthcare group, carving out a specialized position by focusing on the entire value chain-from R&D and manufacturing to distribution-instead of just high-volume wholesale. Its core strength lies in its proprietary nutraceutical and pharmaceutical brands like Sky Premium Life and its Cana Laboratories S.A. manufacturing facility in the European Union.

• Shifting product mix has improved gross profit by 53% in H1 2025, reaching $3.21 million, even as revenue growth was 11.7%.
• The company is projecting an EPS of $0.01 for fiscal 2025, a critical step toward validating its strategic pivot to profitability.
• Expansion into the $164 billion U.S. nutraceuticals market with its proprietary brands is the primary growth driver for the near term, aiming for significantly higher margins than its traditional wholesale segment.

The ultimate success of the strategy will depend on whether the higher-margin segments can scale fast enough to offset the capital demands and debt load. You can read more about the company's long-term philosophy here: Mission Statement, Vision, & Core Values of Cosmos Holdings Inc. (COSM).